Verici Dx Plc
LSE:VRCI
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
|
Verici Dx Plc
LSE:VRCI
|
11m GBP |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
395.1B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
204.9B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
190B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
121.3B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
82.5B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
87.4B AUD |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
41.9B EUR |
Loading...
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
Loading...
|
Market Distribution
| Min | -4 418 600% |
| 30th Percentile | -9.6% |
| Median | 3.1% |
| 70th Percentile | 11.3% |
| Max | 1 135 400% |
Other Profitability Ratios
Verici Dx Plc
Glance View
Verici Dx Plc operates as a developer of advanced clinical diagnostics in organ transplant. The company is headquartered in Franklin, Tennessee and currently employs 8 full-time employees. The company went IPO on 2020-11-03. The principal activity is the development of prognostic and diagnostic tests for kidney transplant patients. The firm's kidney transplant assays use sequencing that defines a personalized risk-profile of each patient over the course of the transplant journey. The firm develops tests to understand how a patient is responding to organ transplants. The firm's products include Clarava and Tuteva. Clarava is a pre-transplant prognosis for the risk of early acute rejection (EAR). Tuteva is a post-transplant diagnostic focused upon acute cellular rejection (ACR), including sub-clinical rejection. The firm's subsidiary is Verici Dx Inc.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Verici Dx Plc is -398.1%, which is above its 3-year median of -12 112.6%.
Over the last 2 years, Verici Dx Plc’s Net Margin has increased from -59 015.8% to -398.1%. During this period, it reached a low of -59 015.8% on Jun 30, 2023 and a high of -111% on Jun 30, 2024.
